Medeze Group

Medeze Group Current Assets

The Current Assets of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is 66.80 M THB. In the previous year, Current Assets was 122.14 M THB — a change of -45.31% (lower).

Current Assets

66.80 MTHB

YoY

-45.31%

Last updated:

Current Assets of Medeze Group is 2025 66.80 M THB. Current Assets of Medeze Group was 2024 122.14 M THB. It decreases by -45.31% lower compared to the previous year.

The Medeze Group Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
130.64 M THB
Jan 1, 2019
141.56 M THB
Jan 1, 2020
66.20 M THB
Jan 1, 2021
498.82 M THB
Jan 1, 2022
522.68 M THB
Jan 1, 2023
59.97 M THB
Jan 1, 2024
122.14 M THB
Jan 1, 2025
66.80 M THB
The Medeze Group Current Assets history
YEARCurrent AssetsYoY
66.80 MTHB-45.31%
122.14 MTHB+103.65%
59.97 MTHB-88.53%
522.68 MTHB+4.78%
498.82 MTHB+653.47%
66.20 MTHB-53.23%
141.56 MTHB+8.36%
130.64 MTHB+38.80%
94.12 MTHB—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

Current Assets of Medeze Group is 66.80 M THB in 2025.

Current Assets of Medeze Group changed from 122.14 M THB to 66.80 M THB, representing a -45.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Medeze Group since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's THB is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Medeze Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medeze Group

All Key Metrics — Medeze Group